Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP7 | P09237 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | FABP4 | P15090 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2299151 | 0.83 | MMP1 (0.42) | MMP1MMP2MMP3MMP7MMP9 | |
| SCHEMBL8973405 | 0.76 | MMP1 (0.47) | MMP1MMP2MMP3MMP7MMP9 | |
| SCHEMBL6077738 | 0.73 | CASP1 (0.56) | MMP1POLBALPLPREPCASP1 | |
| SCHEMBL8972679 | 0.71 | TPSAB1 (0.50) | MMP1POLBALPLFABP4CASP1 | |
| SCHEMBL2299153 | 0.67 | KEAP1 (0.49) | MMP1MMP2MMP9MMP13ITGB1 | |
| SCHEMBL10674988 | 0.65 | FABP4 (0.58) | MMP1MMP2MMP3MMP7MMP9 | |
| SCHEMBL386440 | 0.63 | NSD2 (0.57) | MMP1POLBALPLFABP4GAA | |
| SCHEMBL9100961 | 0.62 | CTRB1 (0.37) | ALDH1A1MAPK1ITGB1ITGA4 | |
| SCHEMBL15903906 | 0.61 | MMP1 (0.50) | MMP1MMP2MMP3MMP7MMP9 | |
| SCHEMBL28617886 | 0.61 | F2 (0.57) | PREPCASP1CA9ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2536694-B1 | Glycine sulfonamides for use as inhibitors of diacylglycerol lipase | BRISTOL MYERS SQUIBB CO (US) | 2014-01-22 | — | — | EP | claimed |
| US-8404741-B2 | Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-26 | — | — | US | claimed |
| EP-2536694-A1 | GLYCINE SULFONAMIDES FOR USE AS INHIBITORS OF DIACYLGLYCEROL LIPASE | Bristol-Myers Squibb Company (US) | 2012-12-26 | — | — | EP | claimed |
| US-20110207749-A1 | Glycine Chroman-6-Sulfonamides for Use as Inhibitors of Diacylglycerol Lipase | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-25 | — | — | US | claimed |
| WO-2011103055-A1 | GLYCINE SULFONAMIDES FOR USE AS INHIBITORS OF DIACYLGLYCEROL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-25 | — | — | WO | claimed |
| EP-2536694-B1 | Glycine sulfonamides for use as inhibitors of diacylglycerol lipase | BRISTOL MYERS SQUIBB CO (US) | 2014-01-22 | — | — | EP | disclosed |
| US-8404741-B2 | Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| EP-2536694-A1 | GLYCINE SULFONAMIDES FOR USE AS INHIBITORS OF DIACYLGLYCEROL LIPASE | Bristol-Myers Squibb Company (US) | 2012-12-26 | — | — | EP | disclosed |
| US-20110207749-A1 | Glycine Chroman-6-Sulfonamides for Use as Inhibitors of Diacylglycerol Lipase | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-25 | — | — | US | disclosed |
| WO-2011103055-A1 | GLYCINE SULFONAMIDES FOR USE AS INHIBITORS OF DIACYLGLYCEROL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207749-A1 | Glycine Chroman-6-Sulfonamides for Use as Inhibitors of Diacylglycerol Lipase | DAGLB, DAGLA, MGLL | MMP1 2630/4885MMP2 1091/4885MMP3 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.